Stuart W. Knight
Imperial College London
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Stuart W. Knight.
American Journal of Human Genetics | 1999
Stuart W. Knight; N.S. Heiss; Tom Vulliamy; S. Greschner; G. Stavrides; G.S. Pai; G. Lestringant; N. Varma; Philip J. Mason; Inderjeet Dokal; Annemarie Poustka
Dyskeratosis congenita is a rare inherited bone marrow-failure syndrome characterized by abnormal skin pigmentation, nail dystrophy, and mucosal leukoplakia. More than 80% of patients develop bone-marrow failure, and this is the major cause of premature death. The X-linked form of the disease (MIM 305000) has been shown to be caused by mutations in the DKC1 gene. The gene encodes a 514-amino-acid protein, dyskerin, that is homologous to Saccharomyces cerevisiae Cbf5p and rat Nap57 proteins. By analogy to the homologues in other species, dyskerin is predicted to be a nucleolar protein with a role in both the biogenesis of ribosomes and, in particular, the pseudouridylation of rRNA precursors. We have determined the genomic structure of the DKC1 gene; it consists of 15 exons spanning a region of 15 kb. This has enabled us to screen for mutations in the genomic DNA, by using SSCP analysis. Mutations were detected in 21 of 37 additional families with dyskeratosis congenita that were analyzed. These mutations consisted of 11 different single-nucleotide substitutions, which resulted in 10 missense mutations and 1 putative splicing mutation within an intron. The missense change A353V was observed in 10 different families and was shown to be a recurring de novo event. Two polymorphisms were also detected, one of which resulted in the insertion of an additional lysine in the carboxy-terminal polylysine domain. It is apparent that X-linked dyskeratosis congenita is predominantly caused by missense mutations; the precise effect on the function of dyskerin remains to be determined.
British Journal of Haematology | 1999
Stuart W. Knight; N. S. Heiss; Tom Vulliamy; C. M. Aalfs; C. McMahon; P. Richmond; A. Jones; Raoul C. M. Hennekam; A. Poustka; Philip J. Mason; Inderjeet Dokal
Hoyeraal‐Hreidarsson (HH) syndrome is a multisystem disorder affecting boys characterized by aplastic anaemia (AA), immunodeficiency, microcephaly, cerebellar‐hypoplasia and growth retardation. Its pathogenesis is unknown. X‐linked dyskeratosis congenita (DC) is an inherited bone‐marrow‐failure syndrome characterized by skin pigmentation, nail dystrophy and leucoplakia which usually develop towards the end of the first decade of life. AA occurs in >90% of cases of DC. We speculated that mutations in the gene responsible for X‐linked DC (DKC1) may account for the HH syndrome, due to the phenotypic similarities between the disease in respect of AA and gender bias. We therefore analysed the DKC1 gene in two HH families. In one family a nucleotide change at position 361(A → G) in exon 5 was found in both affected brothers; in the other family a nucleotide change at position 146(C → T) in exon 3 was found in the affected boys. The finding of these two novel missense DKC1 mutations demonstrates that HH is a severe variant of DC. They also show that mutations in DKC1 can give rise to a very wide clinical spectrum of manifestations. Boys with unexplained AA or immunodeficiency should be tested for mutations in DKC1 even though they may lack diagnostic features of DC.
British Journal of Haematology | 1998
Stuart W. Knight; Tom Vulliamy; Adrian Copplestone; Eliane Gluckman; Philip J. Mason; Inderjeet Dokal
Dyskeratosis congenita (DC) is an inherited disorder characterized by skin pigmentation, nail dystrophy and mucosal leucoplakia. In 1995 a Dyskeratosis Congenita Registry was established at the Hammersmith Hospital. In the 46 families recruited, 76/83 patients were male, suggesting that the major form of DC is X‐linked. As well as a variety of noncutaneous abnormalities, the majority (93%) of patients had bone marrow (BM) failure and this was the principal cause (71%) of early mortality. In addition to BM hypoplasia, some patients also developed myelodysplasia and acute myelod leukaemia. Pulmonary abnormalities were present in 19% of patients. In affected females the phenotype was less severe. Some female carriers of X‐linked DC had clinical features. Carriers of X‐linked DC showed skewed X‐chromosome inactivation patterns (XCIPs), suggesting that cells expressing the normal DC allele have a growth/survival advantage over cells that express the mutant allele. Linkage analysis in multiplex families confirmed that the DKC1 gene, responsible for the X‐linked form of DC, is located within Xq28 and facilitated its positional cloning. The high incidence of BM failure in association with a wide range of somatic abnormalities together with the ubiquitous expression of DKC1 suggest that, as well as having a critical role in normal haemopoiesis, this gene has a key role in normal cell biology.
Nature Genetics | 1998
Nina S. Heiss; Stuart W. Knight; Tom Vulliamy; Sabine M. Klauck; Stefan Wiemann; Philip J. Mason; Annemarie Poustka; Inderjeet Dokal
Blood | 2006
Tom Vulliamy; Anna Marrone; Stuart W. Knight; Amanda J. Walne; Philip J. Mason; Inderjeet Dokal
Blood Cells Molecules and Diseases | 2001
Tom Vulliamy; Stuart W. Knight; Philip J. Mason; Inderjeet Dokal
Human Genetics | 2001
Stuart W. Knight; Tom Vulliamy; Ben Morgan; Koen Devriendt; Philip J. Mason; Inderjeet Dokal
Blood | 1997
Tom Vulliamy; Stuart W. Knight; Inderjeet Dokal; Philip J. Mason
Blood | 1999
Tom Vulliamy; Stuart W. Knight; N.S. Heiss; O.P. Smith; Annemarie Poustka; Inderjeet Dokal; Philip J. Mason
Blood Cells Molecules and Diseases | 1999
Philip J. Mason; David Stevens; Amalia Diez; Stuart W. Knight; Deborah A. Scopes; Tom Vulliamy